Ligand Pharmaceuticals | LGND - Equity Capital And Reserves


Ligand Pharmaceuticals reported $967.52M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Agenus USD -199.08M 22.15M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
Baxter International USD 6.21B 163M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Enviri Corporation USD 233.18M 21.88M Mar/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
Glaxosmithkline GBP 17.42B 4.64B Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Insmed USD 757.49M 52.64M Jun/2026
Intrexon USD 43.17M 75.33M Jun/2024
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Ligand Pharmaceuticals USD 967.52M 29.81M Jun/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Merck USD 41.93B 3.94B Jun/2026
Pacira USD 671.98M 18.08M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Veracyte USD 1.39B 44M Jun/2026